May 7 (Reuters)-
OncoTherapy Science Inc
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Mar 31, 2021 Mar 31, 2020 Mar 31, 2022 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULTS FORECAST H1 FORECAST
Sales 332 mln 316 mln
(+5.1 pct) (+12.7 pct)
Operating loss 1.64 loss 2.19
Recurring loss 1.64 loss 2.20
Net
Net loss 1.56 loss 2.24
EPS loss 8.86 yen loss 13.73 yen
Ann Div NIL NIL NIL
-Q2 Div
-Q4 Div NIL NIL NIL
NOTE - OncoTherapy Science Inc.
*Second Net profit row denotes profit attributable to owners ofthe parent
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4564.T